ZCA
NBIX icon

Zeke Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Zeke Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,798
Closed -$297K – 521
2022
Q3 		$297K Sell
2,798
-398
-12% -$40.4K 0.02% 314
2022
Q2 		$312K Sell
3,196
-886
-22% -$81.8K 0.02% 312
2022
Q1 		$383K Sell
4,082
-223
-5% -$18.9K 0.02% 293
2021
Q4 		$367K Buy
4,305
+297
+7% +$27.3K 0.02% 201
2021
Q3 		$384K Buy
4,008
+542
+16% +$51.2K 0.02% 177
2021
Q2 		$337K Buy
3,466
+489
+16% +$46.9K 0.02% 193
2021
Q1 		$290K Buy
2,977
+324
+12% +$34K 0.02% 217
2020
Q4 		$254K Buy
+2,653
New +$256K 0.02% 226
2020
Q3 		– Sell
-1,918
Closed -$234K – 249
2020
Q2 		$234K Buy
+1,918
New +$212K 0.05% 168
2019
Q2 		– Sell
-8,495
Closed -$748K – 576
2019
Q1 		$748K Buy
8,495
+2,605
+44% +$218K 0.07% 252
2018
Q4 		$421K Buy
+5,890
New +$564K 0.04% 370

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zeke Capital Advisors's NBIX Position: Q4 2022 in Review

Zeke Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 2,798 shares — an estimated $297K sold.

Zeke Capital Advisors first reported a position in NBIX in Q4 2018 and held it in 11 quarters. The position peaked at $748K in Q1 2019. 530 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Zeke Capital Advisors reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Zeke Capital Advisors sold 2,798 Neurocrine Biosciences shares in Q4 2022, an estimated $297K.
  • Zeke Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 11 quarters.
  • Zeke Capital Advisors's Neurocrine Biosciences position peaked at $748K in Q1 2019.
  • 530 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.